Drospirenone and its antialdosterone properties

Climacteric

Volumn 10, Issue SUPPL. 1, 2007, Pages 11-18

  Genazzani, A R ^a   Mannella, P ^a   Simoncini, T ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Aldosterone; Antialdosterone; Cardiovascular; Drospirenone; Progesterone; Progestin

Indexed keywords

15BETA,16BETA METHYLENEMEXRENONE; ALDOSTERONE; ANGIOTENSINOGEN; CONJUGATED ESTROGEN; DROSPIRENONE; DROSPIRENONE PLUS ESTRADIOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPLERENONE; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PLACEBO; PROGESTERONE; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR PARAMETERS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; ESTROGEN THERAPY; HEART FAILURE; HEART MUSCLE; HORMONE SYNTHESIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM EXCRETION; SODIUM RETENTION; SODIUM URINE LEVEL; VASCULARIZATION; WATER RETENTION; WEIGHT GAIN;

ALDOSTERONE ANTAGONISTS; ANDROSTENES; CARDIOVASCULAR SYSTEM; FEMALE; HUMANS; NITRIC OXIDE SYNTHASE TYPE III; RENIN-ANGIOTENSIN SYSTEM;

EID: 33847062987     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601114891     Document Type: Conference Paper

References (34)

1. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311-35
2. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
3. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progesterone. Contraception 2000;62:29-38
4. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985;35:459-71
5. Pollow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progesterone - characterization of binding to different receptor proteins. Contraception 1992;46:561-74
6. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric 2003;6(Suppl 3):49-55
7. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-16
8. Oelkers W, Schöneshöfer M, Schultze G, et al. Prolonged infusions of Ile5-angiotensin-II in sodium replete and deplete man: effects of aldosterone, ACTH, cortisol, blood pressure and electrolyte balance. J Clin Endocrinol Metab 1978;46:402-13
9. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;2171:255-61
10. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905
11. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42
12. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-27
13. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65
14. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1335-64
15. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31:451-8
16. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103:425-31
17. Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998;19:1371-6
18. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76;1259-65
19. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci (Lond) 1998;95:687-92
20. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
21. Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003;107:2512-18
22. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
23. La Vecchia C, Decarli A, Franceschi S, Gentile A, Negri E, Parazzini F. Menstrual and reproductive factors and the risk of myocardial infarction in women under fifty-five years of age. Am J Obstet Gynecol 1987;157:1108-12
24. Skafar DF, Xu R, Morales J, Ram J, Sowers JR. Clinical review 91: Female sex hormones and cardiovascular disease in women. J Clin Endocrinol Metab 1997;82:3913-8
25. Herrington DM. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation 2003;107:2-4
26. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
27. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
28. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
29. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease; the Women's Health Initiative. Arch Intern Med 2006;166:357-65
30. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in overiectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 1990;10:1051-7
31. Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 1998;18:1164-71
32. Liao JK. In Panza JA, Cannon ROI, eds. Endothelium, Nitric Oxide and Atherosclerosis. Armonk, New York: Futura Publishing Co., Inc., 1999:119-32
33. Kleinert H, Wallerath T, Euchenhofer C, Ihrig-Biedert I, Li H, Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998;31:582-8
34. Simoncini T, Mannella P, Fornari L, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004;145:5745-56